Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin
Jiang E, Park E, Nguyen C, Yoon J, Hsieh Y, Loh M, Muschen M, Kahn M, Kim Y. Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin. Blood 2010, 116: 3264. DOI: 10.1182/blood.v116.21.3264.3264.Peer-Reviewed Original ResearchICG-001 treatmentMedian survival timeICG-001Β-cateninΓ-cateninDose-dependent downregulationSaline control groupAcute lymphoblastic leukemiaSmall molecule specific inhibitorNOD/SCIDReduction of survivinΒ-catenin siRNAReal-time RT-PCRDownregulation of survivinΒ-catenin expressionDecrease of survivinOvercoming Drug ResistanceTime RT-PCRWestern blot analysisPoor prognosisLymphoblastic leukemiaColon cancer cellsSurvival timeShRNA controlXenograft cellsAdjuvant CD49d Blockade Eradicates Chemoresistant ALL
Hsieh Y, Park E, Jiang E, Dauber K, Chudziak D, Schaefer P, Klemm L, Scharman C, Kang E, Koo H, Loh M, Hofmann W, Heisterkamp N, Muschen M, Shimada H, Bonig H, Kim Y. Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. Blood 2010, 116: 869. DOI: 10.1182/blood.v116.21.869.869.Peer-Reviewed Original ResearchAcute lymphocytic leukemiaNOD/SCID miceBone marrow cellsSCID miceSurvival timeB-lineage acute lymphocytic leukemiaCounter-receptor VCAM-1Drug resistanceNOD/SCID xenograft modelLong-term side effectsMarrow cellsChemotherapy-resistant leukemiaDose-limiting toxicityLeukemia cellsSaline-treated groupCell adhesion-mediated drug resistanceMedian survival timeImmunocompetent mouse modelRelapse of leukemiaSCID xenograft modelAcute lymphoblastic leukemiaMurine leukemiaProlonged survival timeNew treatment modalitiesAdhesion-mediated drug resistance